Replimune Group, Inc. logo

Replimune Group, Inc.

NASDAQ:REPL

Overview | Financials
Company Name Replimune Group, Inc.
Symbol REPL
Currency USD
Price 8.82
Market Cap 541,681,182
Dividend Yield 0%
52-week-range 4.92 - 24.81
Industry Biotechnology
Sector Healthcare
CEO Mr. Philip Astley-Sparke F.S.A., FSA
Website https://www.replimune.com

An error occurred while fetching data.

About Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus

Related Stocks

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

6.79 USD

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.22 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

3.77 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

6.04 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

8.64 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

14.48 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

uniQure N.V. logo

uniQure N.V.

QURE

5.28 USD

Financials

Numbers are in millions USD

Numbers are in millions USD